Ikatibant Teva

Icatibant acetate, the active ingredient in Ikatibant Teva, is a bradykinin B2 receptor antagonist presented as a sterile solution for subcutaneous injection. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, helping to reduce swelling and associated discomfort.

GNH USA supplies Ikatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with a focus on reliable sourcing for the European market and other regulated regions.

Ikatibant Teva acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

- Hereditary angioedema type I: rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: rapid reduction of swelling during acute attacks. - Hereditary angioedema with normal C1‑inhibitor (off‑label): may be considered under specialist supervision.

Ikatibant Teva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the injection site. - Injection site erythema: redness around the injection area. - Injection site swelling: localized edema. - Nausea: mild gastrointestinal upset. - Headache: transient head discomfort. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or swelling of the face. - Anaphylaxis: severe, life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling. - Thrombocytopenia: reduced platelet count. - Injection‑site infection: signs of local infection.

Before prescribing Ikatibant Teva, clinicians should consider several safety measures.

- Assess patient history: confirm diagnosis of hereditary angioedema. - Monitor for hypersensitivity: watch for rash, itching, or breathing difficulty. - Avoid in patients with known hypersensitivity to icatibant acetate. - Use with caution in pregnant or breastfeeding women: limited safety data are available. - Do not mix with other injectable solutions in the same syringe. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ikatibant Teva can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid): - Concurrent use with ACE inhibitors: may increase bradykinin levels and raise the risk of angioedema. - Co‑administration with other bradykinin B2 antagonists: additive antagonism is not recommended.

Moderate Interactions (Monitor Closely): - Concurrent use with other subcutaneous biologics: monitor injection‑site reactions. - Use with antihistamines or corticosteroids: may mask early signs of hypersensitivity. - Use with diuretics: monitor blood pressure for unexpected changes.